These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10070817)

  • 1. Lowering fibrinogen levels: clinical update. BIP Study Group. Bezafibrate Infarction Prevention.
    Behar S
    Blood Coagul Fibrinolysis; 1999 Feb; 10 Suppl 1():S41-3. PubMed ID: 10070817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
    Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
    Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
    Goldbourt U; Brunner D; Behar S; Reicher-Reiss H
    Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
    Goldenberg I; Benderly M; Goldbourt U;
    J Am Coll Cardiol; 2008 Jan; 51(4):459-65. PubMed ID: 18222357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease.
    Haim M; Benderly M; Tanne D; Matas Z; Boyko V; Fisman EZ; Tenenbaum A; Zimmlichman R; Battler A; Goldbourt U; Behar S
    Am Heart J; 2007 Dec; 154(6):1095-101. PubMed ID: 18035081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
    Tenenbaum A; Motro M; Fisman EZ; Tanne D; Boyko V; Behar S
    Arch Intern Med; 2005 May; 165(10):1154-60. PubMed ID: 15911729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease: the Bezafibrate Infarction Prevention Study.
    Haim M; Boyko V; Goldbourt U; Battler A; Behar S
    Arch Intern Med; 2004 Feb; 164(4):433-9. PubMed ID: 14980995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
    Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
    Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
    Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
    Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
    Tenenbaum A; Motro M; Fisman EZ; Schwammenthal E; Adler Y; Goldenberg I; Leor J; Boyko V; Mandelzweig L; Behar S
    Circulation; 2004 May; 109(18):2197-202. PubMed ID: 15123532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study.
    Ye P; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC;
    J Am Geriatr Soc; 2007 Jul; 55(7):1015-22. PubMed ID: 17608873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD40 ligand and risk of ischemic stroke or coronary events in patients with chronic coronary heart disease.
    Tanne D; Haim M; Goldbourt U; Boyko V; Reshef T; Adler Y; Benderly M; Mekori YA; Behar S
    Int J Cardiol; 2006 Mar; 107(3):322-6. PubMed ID: 16503253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased plasma levels of fibrinogen in acute and chronic ischemic coronary syndromes.
    Abrignani MG; Novo G; Di Girolamo A; Caruso R; Tantillo R; Braschi A; Braschi GB; Strano A; Novo S
    Cardiologia; 1999 Dec; 44(12):1047-52. PubMed ID: 10687254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study).
    Brodov Y; Behar S; Goldenberg I; Boyko V; Chouraqui P
    Am J Cardiol; 2009 Jul; 104(2):194-8. PubMed ID: 19576345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum homocysteine and long-term risk of myocardial infarction and sudden death in patients with coronary heart disease.
    Haim M; Tanne D; Goldbourt U; Doolman R; Boyko V; Brunner D; Sela BA; Behar S
    Cardiology; 2007; 107(1):52-6. PubMed ID: 16763372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
    Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).
    Li JJ; Lu ZL; Kou WR; Chen Z; Wu YF; Yu XH; Zhao YC;
    J Clin Pharmacol; 2009 Aug; 49(8):947-56. PubMed ID: 19602720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.